High-Dose IV Iron Reduces Myocardial Infarction in Hemodialysis
Until now, no other treatment has been shown to reduce heart attack risk in patients on dialysis.
Myocardial Infarction
New Drugs Approved in 2021
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Polypharmacy May Increase Risks for Kidney Failure, Cardiovascular Events
Avoiding unnecessary medications in CKD might reduce the risks for adverse outcomes, investigators suggested.
USPSTF: Starting Aspirin in Patients 60 or Older for Primary CVD Prevention Not Recommended
Starting aspirin in patients 60 years or older to prevent a first heart attack or stroke is not recommended.
Acute Myocarditis Rare After COVID-19 mRNA Vaccination in Adults
Incidence of myocarditis 5.8 cases per 1 million adults after the second dose; safety signal for increased myocarditis seen in young men
Finerenone Provides CV, Renal Benefits in Diabetes Across CKD Spectrum
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
Fixed-Dose Combination Therapies Reduce Cardiovascular Risk
Fixed-dose combo with BP-lowering meds, statin, and aspirin yields largest reduction in cardiovascular risk
New Drug Product: Kerendia
This slideshow show drug information for Kerendia. Click here for the complete Kerendia monograph.
Risk for Myocarditis in Young Who Get Moderna Shots May Be Greater Than Thought
However, health officials emphasize that COVID-19 puts someone at much greater risk for heart inflammation than getting the vaccine does
Review Compiles Myocarditis Cases Associated With COVID-19
COVID-19-related myocarditis profiled from 42 cases reported in articles published from December 2019 through January 5, 2021
